Results 61 to 70 of about 188,791 (289)

Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. [PDF]

, 2018
The anti-CD20 antibody ocrelizumab, approved for treatment of multiple sclerosis, leads to rapid elimination of B cells from the blood. The extent of B cell depletion and kinetics of their recovery in different immune compartments is largely unknown ...
Bernard, Claude CA, Brück, Wolfgang, Feldmann, Linda, Häusler, Darius, Häusser-Kinzel, Silke, Lehmann-Horn, Klaus, Lepennetier, Gildas, Torke, Sebastian, Weber, Martin S, Zamvil, Scott S   +9 more
core   +1 more source

[18F]Fluorodeprenyl‐D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate [18F]fluorodeprenyl‐D2 ([18F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods [18F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and ...
Julia S. Dorneich, Jonathan A. Gernert, Hanna Zimmermann, Lisa Tagnin, Marianthi Zeinaki, Laura Sanzo, Letizia Vogler, Elisabeth Kaufmann, Justina Dargvainiene, Frank Leypoldt, Gérard N. Bischof, Robert Perneczky, Boris‐Stephan Rauchmann, Simon Lindner, Günter U. Höglinger, Rudolf A. Werner, Martin Kerschensteiner, Tania Kümpfel, Matthias Brendel, Franziska S. Thaler   +19 more
wiley   +1 more source

Applying Rituximab During the Conditioning Regimen Prevents Epstein–Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children’s Cohort: A Retrospective Case–Control Study

Infectious Diseases and Therapy, 2023
Introduction Since hematopoietic stem cell transplant (HSCT) is an important therapy for malignant and non-malignant pediatric diseases, improving transplant-related mortality remains a challenge. Currently, rituximab, a monoclonal antibody of anti-CD20,
Yongsheng Ruan, Libai Chen, Tingting Luo, Danfeng Xie, Wei Cao, Xuan Liu, Qiujun Liu, Yuhua Xiao, Cuiling Wu, Jianyun Wen, Juan Li, Jiangnan Meng, Xuedong Wu, Xiaoqin Feng   +13 more
doaj   +1 more source

The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study

Frontiers in Immunology, 2022
Rituximab is used to eliminate B cells as a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B cells. To explore the impact of rituximab administered before transplantation, we implemented a retrospective, monocentric ...
Xiya Wei, Xiya Wei, Yiyu Xie, Yiyu Xie, Ruoyu Jiang, Ruoyu Jiang, Huiyu Li, Huiyu Li, Heqing Wu, Heqing Wu, Yuqi Zhang, Yuqi Zhang, Ling Li, Ling Li, Shiyuan Zhou, Shiyuan Zhou, Xiao Ma, Xiao Ma, Zaixiang Tang, Jun He, Jun He, Depei Wu, Depei Wu, Xiaojin Wu, Xiaojin Wu   +24 more
doaj   +1 more source

Primary CNS Lymphoma [PDF]

, 2014
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is an aggressive malignancy that exhibits unique biological features and characteristic clinical behaviour, with overall long-term survival rates of around 20–40 %.
Cwynarski, K, Fox, CP, Phillips, EH
core   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

PRIORITY Study: Baseline and Post-Rituximab Immune Profiles in a Pediatric Cohort

Journal of Human Immunity
BackgroundPediatric utilization of rituximab encompasses autoimmune, renal, hematologic, and neurologic conditions. Its association with secondary hypogammaglobulinemia and unmasking of inborn errors of immunity is well recognized.
Dr. Jenny Garkaby, Dr. Andrew Wong-Pack, Dr. Leena Ahmed, Dr. Tania Cellucci, Dr. Dua Meghna, Dr. Rahul Chanchlani, Zaina Khan, Zaeem Nadeem   +7 more
doaj   +1 more source

Rituximab in Minimal Change Disease

Canadian Journal of Kidney Health and Disease, 2017
Treatment with rituximab, a monoclonal antibody against the B-lymphocyte surface protein CD20, leads to the depletion of B cells. Recently, rituximab was reported to effectively prevent relapses of glucocorticoid-dependent or frequently relapsing minimal
Nima Madanchi, Martin Bitzan, Tomoko Takano   +2 more
doaj   +1 more source

Combination therapy for management of pemphigus patients with unexpected therapeutic response to rituximab: A report of five cases

Clinical Case Reports, 2023
Key Clinical Message The immunosuppressant agents should be considered earlier in the course of treatment with rituximab, possibly after the unfavorable response at first cycle of treatment, especially in male patients and those with high BMI.
Zeinab Aryanian, Insha Zainab Riyaz, Kamran Balighi, Ali Ahmadzade, Hamid Reza Mahmoudi, Arghavan Azizpour, Parvaneh Hatami   +6 more
doaj   +1 more source

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]

, 2019
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat, Barr, Paul M., Burger, Jan A., Coutre, Steven E., Dai, Sandra, Dean, James P., Devereux, Stephen, Ghia, P, Grosicki, Sebastian, Hillmen, Peter, Kipps, Thomas J., Lal, Indu, McCarthy, Helen, Moreno, Carol, Offner, Fritz, Owen, Carolyn, Robak, Tadeusz, Simpson, David, Tedeschi, Alessandra, Universitat Autònoma de Barcelona   +19 more
core   +3 more sources